The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

被引:679
作者
Alao, John P. [1 ]
机构
[1] Univ Gothenburg, Lundberg Lab, Dept Cell & Mol Biol, S-40530 Gothenburg, Sweden
关键词
D O I
10.1186/1476-4598-6-24
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclin D1 is an important regulator of cell cycle progression and can function as a transcriptionl co-regulator. The overexpression of cyclin D1 has been linked to the development and progression of cancer. Deregulated cyclin D1 degradation appears to be responsible for the increased levels of cyclin D1 in several cancers. Recent findings have identified novel mechanisms involved in the regulation of cyclin D1 stability. A number of therapeutic agents have been shown to induce cyclin D1 degradation. The therapeutic ablation of cyclin D1 may be useful for the prevention and treatment of cancer. In this review, current knowledge on the regulation of cyclin D1 degradation is discussed. Novel insights into cyclin D1 degradation are also discussed in the context of ablative therapy. A number of unresolved questions regarding the regulation of cellular cyclin D1 levels are also addressed.
引用
收藏
页数:16
相关论文
共 162 条
  • [71] Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells
    Huang, JW
    Shiau, CW
    Yang, YT
    Kulp, SK
    Chen, KF
    Brueggemeier, RW
    Shapiro, CL
    Chen, CS
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (04) : 1342 - 1348
  • [72] A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells
    Huang, TS
    Lee, CC
    Chao, Y
    Shu, CH
    Chen, LT
    Chen, LL
    Chen, MH
    Yuan, CC
    Whang-Peng, J
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (07) : 997 - 1002
  • [73] Hui R, 2002, CANCER RES, V62, P6916
  • [74] Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation
    Iwata, S
    Sato, Y
    Asada, M
    Takagi, M
    Tsujimoto, A
    Inaba, T
    Yamada, T
    Sakamoto, S
    Yata, J
    Shimogori, T
    Igarashi, K
    Mizutani, S
    [J]. ONCOGENE, 1999, 18 (01) : 165 - 172
  • [75] Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
    Jang, MS
    Cai, EN
    Udeani, GO
    Slowing, KV
    Thomas, CF
    Beecher, CWW
    Fong, HHS
    Farnsworth, NR
    Kinghorn, AD
    Mehta, RG
    Moon, RC
    Pezzuto, JM
    [J]. SCIENCE, 1997, 275 (5297) : 218 - 220
  • [76] Janus A, 2005, CELL MOL BIOL LETT, V10, P479
  • [77] Joe AK, 2002, CLIN CANCER RES, V8, P893
  • [78] Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
    Johnstone, RW
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) : 287 - 299
  • [79] Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?
    Johnstone, RW
    Licht, JD
    [J]. CANCER CELL, 2003, 4 (01) : 13 - 18
  • [80] KATO J, 1993, GENE DEV, V7, P331